Evidence map›Paper›PMID 35754103›Full record

ArticleAddiction biology2022

Recovery of dopaminergic system after cocaine exposure and impact of a long-acting cocaine hydrolase.

Jing Deng, Ting Zhang, Xirong Zheng, Linyue Shang, Chang-Guo Zhan, Fang Zheng

Open access · greenAbstract read
In one paragraph

Article in Addiction biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jing DengMolecular Modeling and Biopharmaceutical Center, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky, 40536, USA.
Ting ZhangMolecular Modeling and Biopharmaceutical Center, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky, 40536, USA.
Xirong ZhengMolecular Modeling and Biopharmaceutical Center, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky, 40536, USA.
Linyue ShangMolecular Modeling and Biopharmaceutical Center, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky, 40536, USA.
Chang-Guo ZhanMolecular Modeling and Biopharmaceutical Center, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky, 40536, USA.ORCID 0000-0002-4128-7269
Fang ZhengMolecular Modeling and Biopharmaceutical Center, University of Kentucky, 789 South Limestone Street, Lexington, Kentucky, 40536, USA.
University of Kentucky · US

Funding

Development of a Long-acting Enzyme Therapy for Treatment of Cocaine AbuseU01DA051079 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2020 to 2022
$11.8M
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine AbuseUH3DA041115 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2017 to 2019
$3.8M
Long-lasting cocaine-metabolizing enzyme for cocaine addiction treatmentR01DA035552 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2013 to 2015
$3.4M
Redesign of Butyrylcholinesterase for Cocaine MetabolismR01DA013930 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2003 to 2010
$2.4M
Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine AbuseUH2DA041115 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2015 to 2016
$2.2M
Development of a Cocaine-Metabolizing Enzyme for Drug Overdose TreatmentR01DA032910 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHAN, CHANG-GUO · 2012 to 2015
$1.8M
Validation of ghrelin hydrolysis as an effective approach to treatment of substance use disordersU18DA052319 · NIDA · UNIVERSITY OF KENTUCKY · PI ZHENG, FANG · 2020 to 2020
$230k
NIDA NIH HHS R01 DA013930NIDA NIH HHS R01 DA032910NIDA NIH HHS R01 DA035552NIDA NIH HHS U01 DA051079NIDA NIH HHS U18 DA052319NIDA NIH HHS UH2 DA041115NIDA NIH HHS UH3 DA041115
6 · The paper itself

Abstract

Dysregulation of dopamine transporters (DAT) within the dopaminergic system is an important biomarker of cocaine exposure. Depending on cocaine amount in-taken, one-time exposure in rats could lead to most (>95% of total) of DAT translocating to plasma membrane of the dopaminergic neurons compared to normal DAT distribution (~5.7% on the plasma membrane). Without further cocaine exposure, the time course of striatal DAT distribution, in terms of intracellular and plasma membrane fractions of DAT, represents a recovery process of the dopaminergic system. In this study, we demonstrated that after an acute cocaine exposure of 20 mg/kg (i.p.), the initial recovery process from days 1 to 15 in rats was relatively faster (from >95% on day 1 to ~35.4% on day 15). However, complete recovery of the striatal DAT distribution may take about 60 days. In another situation, with repeated cocaine exposures for once every other day for a total of 17 doses of 20 mg/kg cocaine (i.p.) from days 0 to 32, the complete recovery of striatal DAT distribution may take an even longer time (about 90 days), which represents a consequence of chronic cocaine use. Further, we demonstrated that a highly efficient Fc-fused cocaine hydrolase, CocH5-Fc(M6), effectively blocked cocaine-induced hyperactivity and DAT trafficking with repeated cocaine exposures by maintaining a plasma CocH5-Fc(M6) concentration ≥58.7 ± 2.9 nM in rats. The cocaine hydrolase protected dopaminergic system and helped the cocaine-altered DAT distribution to recover by preventing the dopaminergic system from further damage by cocaine.

Indexed as

CocaineAnimalsCarboxylic Ester HydrolasesDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsRatsRecombinant ProteinsCarboxylic Ester HydrolasesCocainecocaine hydrolaseDopamineDopamine Plasma Membrane Transport ProteinsDopamine Uptake InhibitorsRecombinant Proteinscocainecocaine hydrolasedopamine transporter

Identifiers

PMID35754103
PMCPMC9245253
OpenAlexW4280648370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.